Literature DB >> 22212932

Signaling pathways governing tumor angiogenesis.

Toshiharu Sakurai1, Masatoshi Kudo.   

Abstract

Angiogenesis is regulated by the highly coordinated function of various proteins with pro- and antiangiogenic functions. Proangiogenic factors include vascular endothelial growth factor (VEGF), fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, transforming growth factor, angiopoietins, and several chemokines; antiangiogenic factors include thrombospondin-1, angiostatin, and endostatin. Matrix metalloproteinases display a dual role in vascular development. Notch signaling affects remodeling of the primary vascular network of uniformly sized vessels into functionally and morphologically distinct arteries, veins, and capillaries. Tumors, described as 'wounds that never heal', lose the appropriate balance among these factors. Although VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to make additional gains. Here, we highlight recent advances in our understanding of the regulation of tumor angiogenesis and discuss the potential of molecular targeting as a new therapeutic approach.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212932     DOI: 10.1159/000333256

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  77 in total

1.  IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma.

Authors:  Ying Liu; Wenqing Jiang; Jing Liu; Shimin Zhao; Ji Xiong; Ying Mao; Yin Wang
Journal:  J Neurooncol       Date:  2012-07-08       Impact factor: 4.130

2.  MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs.

Authors:  Mina Soufi-Zomorrod; Abbas Hajifathali; Fatemeh Kouhkan; Mahshid Mehdizadeh; Seyed Mohammad Ali Hosseini Rad; Masoud Soleimani
Journal:  Tumour Biol       Date:  2016-01-20

Review 3.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

4.  The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.

Authors:  Ding Li; Stacey D Finley
Journal:  Integr Biol (Camb)       Date:  2018-04-23       Impact factor: 2.192

5.  Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  You-Bing Zheng; Qing-Wen Meng; Wei Zhao; Bing Liu; Jian-Wen Huang; Xu He; Yong Li; Bao-Shan Hu; Li-Gong Lu
Journal:  Med Oncol       Date:  2014-01-18       Impact factor: 3.064

Review 6.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

7.  From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis.

Authors:  Ilaria Giusti; Simona Delle Monache; Marianna Di Francesco; Patrizia Sanità; Sandra D'Ascenzo; Giovanni Luca Gravina; Claudio Festuccia; Vincenza Dolo
Journal:  Tumour Biol       Date:  2016-07-22

Review 8.  Protein kinases and associated pathways in pluripotent state and lineage differentiation.

Authors:  Melina Shoni; Kathy O Lui; Demetrios G Vavvas; Michael G Muto; Ross S Berkowitz; Nikolaos Vlahos; Shu-Wing Ng
Journal:  Curr Stem Cell Res Ther       Date:  2014       Impact factor: 3.828

9.  The enzyme L-isoaspartyl (D-aspartyl) methyltransferase is required for VEGF-dependent endothelial cell migration and tubulogenesis.

Authors:  Amira Ouanouki; Richard R Desrosiers
Journal:  Mol Cell Biochem       Date:  2016-01-06       Impact factor: 3.396

10.  Sphingosine-1-phosphate induces VEGF-C expression through a MMP-2/FGF-1/FGFR-1-dependent pathway in endothelial cells in vitro.

Authors:  Chi-hao Chang; Yuan-li Huang; Ming-kwang Shyu; Shee-uan Chen; Chih-hsin Lin; Tsai-kai Ju; JenHer Lu; Hsinyu Lee
Journal:  Acta Pharmacol Sin       Date:  2013-02-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.